Get the Stockscreener App
3.80
2.59%
0.13
Corvus Pharmaceuticals Inc stock is traded at $3.80, with a volume of 436.85K.
It is up +2.59% in the last 24 hours and up +7.57% over the past month.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
See More
Previous Close:
$3.67
Open:
$3.67
24h Volume:
436.85K
Relative Volume:
0.45
Market Cap:
$292.28M
Revenue:
-
Net Income/Loss:
$-27.03M
P/E Ratio:
-6.7857
EPS:
-0.56
Net Cash Flow:
$-23.97M
1W Performance:
+3.72%
1M Performance:
+7.57%
6M Performance:
-60.03%
1Y Performance:
+86.39%
1-Day Range:
$3.62
$3.805
1-Week Range:
$3.38
$3.78
52-Week Range:
$1.75
$10.00
Corvus Pharmaceuticals Inc Stock (CRVS) Company Profile
Name
Corvus Pharmaceuticals Inc
Sector
Industry
Phone
(650) 900-4520
Address
863 MITTEN ROAD, BURLINGAME, CA
Compare CRVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVS
Corvus Pharmaceuticals Inc
|
3.79 | 283.78M | 0 | -27.03M | -23.97M | -0.56 |
|
ONC
Beigene Ltd Adr
|
240.40 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.89 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
595.26 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.67 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
Corvus Pharmaceuticals Inc Stock (CRVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-02-25 | Initiated | H.C. Wainwright | Buy |
| Aug-18-23 | Initiated | Oppenheimer | Outperform |
| Dec-01-21 | Resumed | Jefferies | Buy |
| May-27-21 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-10-21 | Downgrade | Mizuho | Buy → Neutral |
| Sep-12-19 | Initiated | Mizuho | Buy |
| May-29-19 | Initiated | ROTH Capital | Buy |
| Aug-24-17 | Upgrade | Credit Suisse | Underperform → Neutral |
| May-01-17 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-18-16 | Initiated | Credit Suisse | Outperform |
| Apr-18-16 | Initiated | Guggenheim | Buy |
View All
Corvus Pharmaceuticals Inc Stock (CRVS) Latest News
Corvus Pharmaceuticals targets expanded soquelitinib trials with Q4 2025 results expected - MSN
CRVS: Mizuho Adjusts Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positiv - GuruFocus
Corvus Pharmaceuticals (CRVS) Target Price Adjusted Amid Positive Drug Data | CRVS Stock News - GuruFocus
Mizuho Adjusts Price Target on Corvus Pharmaceuticals to $11 From $12, Maintains Outperform Rating - marketscreener.com
Corvus Pharmaceuticals (NASDAQ:CRVS) Upgraded by StockNews.com to Hold Rating - Defense World
Corvus Pharmaceuticals (CRVS) Sees Increased Investor Interest A - GuruFocus
Corvus Pharmaceuticals (CRVS) Sees Notable Increase in Borrow Ra - GuruFocus
Spotlight On Top Penny Stocks For May 2025 - simplywall.st
Corvus Pharmaceuticals’ (CRVS) Outperform Rating Reiterated at Oppenheimer - Defense World
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2025 Earnings Call Transcript - Insider Monkey
Corvus Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS S - GuruFocus
Corvus Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CRVS: Oppenheimer Raises Price Target for Corvus Pharma | CRVS Stock News - GuruFocus
Corvus Gets Price Target Hike From Oppenheimer On Positive Drug Trial Results: Retail’s Pleased - Asianet Newsable
Why Is Corvus Pharmaceuticals Stock Soaring On Friday? - Benzinga
Corvus Pharmaceuticals shares surge on positive trial results By Investing.com - Investing.com Nigeria
Corvus Pharmaceuticals shares surge on positive trial results - Investing.com
Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $17 From $15, Maintains Outperform Rating - marketscreener.com
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - Yahoo
Corvus: Q1 Earnings Snapshot - New Haven Register
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Corvus reports positive phase 1 trial results for atopic dermatitis drug - Investing.com
Corvus Pharma Reports 'Favorable' Interim Phase 1 Results in Atopic Dermatitis Trial; Shares Surge Premarket - marketscreener.com
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... By GuruFocus - Investing.com Canada
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - The Manila Times
Corvus Pharmaceuticals Reports Promising Q1 2025 Results - TipRanks
10 Low Risk High Reward Stocks Set to Triple by 2030 - Insider Monkey
Corvus Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CRVS) - Seeking Alpha
Earnings call transcript: Corvus Pharmaceuticals Q1 2025 sees stock surge despite EPS miss - Investing.com India
Corvus Pharmaceuticals Reports Positive Phase 1 Trial Results - TipRanks
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of - GlobeNewswire
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Stock Titan
Post-Trade Analysis: Corvus Pharmaceuticals Inc (CRVS) Slides -6.03, Closing at 3.35 - DWinneX
Corvus Pharmaceuticals Inc (CRVS) deserves deeper analysis - uspostnews.com
CRVS Stock: More Upside For Corvus Pharmaceuticals Inc (NASDAQ: CRVS)? - Marketing Sentinel
Corvus Pharmaceuticals Inc [CRVS] Investment Appeal on the Rise - knoxdaily.com
Gaining Ground: Corvus Pharmaceuticals Inc (CRVS) Closes Lower at 3.50, Down -3.58 - DWinneX
Market Resilience: Corvus Pharmaceuticals Inc (CRVS) Finishes Strong at 3.38, Up 0.30 - DWinneX
Press Release Distribution & PR Platform - ACCESS Newswire
An analyst sees good growth prospects for Corvus Pharmaceuticals Inc (CRVS) - Sete News
Corvus Pharmaceuticals Inc (CRVS) deserves closer scrutiny - uspostnews.com
Upward Trajectory: Corvus Pharmaceuticals Inc (CRVS) Posts a Gaine, Closing at 3.52 - DWinneX
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - EMEA Tribune
Corvus Pharmaceuticals Inc [CRVS] Investment Guide: What You Need to Know - knoxdaily.com
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - The Manila Times
Novel Atopic Dermatitis Treatment Shows Promise: Key Phase 1 Trial Results To Be Unveiled at Major Conference - Stock Titan
Corvus Pharmaceuticals Inc Stock (CRVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):